Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Blood (2024) 144 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2024-205223

Published: 2024

Journal Articles

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie, Ramya Pulluru, Christine Crider, Mehrdad Shakib-Azar, Neena Kennedy, Vikram Raghunathan, Christina Poh, Mengyang Di, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 4634.2.

https://doi.org/10.1182/blood-2024-204491

Published: 2024

Journal Articles

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Blood (2024) 144 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2024-206512

Published: 2024

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, Neena Kennedy, Mengyang Di, Ajay K. Gopal, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Heather Rasmussen, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Stephen D. Smith

Blood (2024) 144 (Supplement 1): 783.

https://doi.org/10.1182/blood-2024-208269

Published: 2024

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Christina Poh, Jenna M. Voutsinas, Ivan Huang, Edus H. Warren, Caitlin A. Crimp, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2024-194018

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2024-206047

Published: 2024

Journal Articles

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Thomas M Kuczmarski, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Yolanda D Tseng, Hongyan Du, Jacquelin Vandermeer, Alyssa Kelly, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal, Ryan C Lynch

Blood (2024) 144 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2024-208412

Published: 2024

Journal Articles

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2024-206601

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Laura Samples, Sirin Khajaviyan, Sara Keshmiri, Ryan S. Basom, Ryan C Lynch, Vikram Raghunathan, Mengyang Di, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Christina Poh, Stephanie Louie, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 6785.

https://doi.org/10.1182/blood-2024-211971

Published: 2024

Journal Articles

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Carrie I Ho, Mengyang Di, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Mazyar Shadman, Stephen D. Smith, Brian G. Till, Paul S Martin, Chaitra S. Ujjani, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1661.2.

https://doi.org/10.1182/blood-2024-204154

Published: 2024

Journal Articles

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2224.

https://doi.org/10.1182/blood-2023-184728

Published: 2023

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Laura Samples, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Hania Shakalia, Stephanie Louie, David G Maloney, Christina Poh, Brian G Till, Stephen D Smith, Ajay K Gopal, Chaitra S Ujjani, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2023-186775

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Stephen D Smith, Chaitra S Ujjani, Susan Ottemiller, Melissa Mary Fessel, Bonnie Joy, Jacob DeBell, Joshua Dizon, Ryan Park, Heather Rasmussen, Jacquelin Vandermeer, Jenna M Voutsinas, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2023-174292

Published: 2023

Journal Articles

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Laura Samples, Chaitra S Ujjani, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Stephanie Louie, Christina Poh, Stephen D Smith, Brian G Till, David G Maloney, Ajay K Gopal, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2023-187129

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only